Nature, prevalence and clinical significance. Barcelona, Spain

Similar documents
Chronic Effects of Dopaminergic Replacement on Cognitive Function in Parkinson s Disease: A Two-Year Follow-Up Study of Previously Untreated Patients

Clinical Features and Treatment of Parkinson s Disease

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

Neuropsychological Evaluation of

Continuous dopaminergic stimulation

Cognitive-Motor Interference in Persons with Parkinson Disease

NEUROPSYCHOMETRIC TESTS

PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET

Non-motor symptoms as a marker of. Michael Samuel

DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services

Parkinsonian Disorders with Dementia

Behavioural Correlates of Cognitive Skill Learning in Parkinson s Disease

Appendix N: Research recommendations

Evolution of cognitive dysfunction in an incident Parkinson s disease cohort

Treatment of sleep disorders in

The Neuropsychology of

M P---- Ph.D. Clinical Psychologist / Neuropsychologist

Dementia in Parkinson s disease:

Process of a neuropsychological assessment

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III

Correlation between motor and cognitive functions in the progressive course of Parkinson s disease

Late Stage PD: clinical problems & management issues

A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease

Use of the Pill Questionnaire to detect cognitive deficits and assess their impact on daily life in patients with Parkinson s disease

Dementia and Alzheimer s disease

Use a diagnostic neuropsychology HOW TO DO IT PRACTICAL NEUROLOGY

Clinical Study A New Approach for the Quantitative Evaluation of the Clock Drawing Test: Preliminary Results on Subjects with Parkinson s Disease

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

Cognition in Parkinson's Disease and the Effect of Dopaminergic Therapy

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

02/04/2015. The structure of the talk. Dementia as a motor disorder. Movement, cognition & behaviour. Example 1. Example 2

University of Alberta

Cognitive Function in Early and Advanced Parkinson s disease

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Biological Risk Factors

SCIENTIFIC DISCUSSION

THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME

The Frontal Lobes. Anatomy of the Frontal Lobes. Anatomy of the Frontal Lobes 3/2/2011. Portrait: Losing Frontal-Lobe Functions. Readings: KW Ch.

21/05/2018. Today s webinar will answer. Presented by: Valorie O Keefe Consultant Psychologist

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician

SOCIABLE - NEXT GENERATION COGNITIVE TRAINING USING MULTI-TOUCH SURFACE COMPUTERS

Hallucinations and conscious access to visual inputs in Parkinson s disease

Erin Cullnan Research Assistant, University of Illinois at Chicago

Table 1: Summary of measures of cognitive fatigability operationalised in existing research.

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

CANTAB Test descriptions by function

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Non Alzheimer Dementias

University of Groningen. Visual hallucinations in Parkinson's disease Meppelink, Anne Marthe

Basal ganglia motor circuit

Hill, Elisabeth L Executive dysfunction in autism. Trends in Cognitive Sciences, 8(1), pp ISSN [Article]

University of Zagreb Medical School Repository

Mild cognitive impairment in Parkinson s disease: a distinct clinical entity?

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia

Alzheimer s disease dementia: a neuropsychological approach

shows syntax in his language. has a large neocortex, which explains his language abilities. shows remarkable cognitive abilities. all of the above.

Working memory in medicated patients with Parkinson's disease: the central executive seems to work

Behavioral Aspects of Parkinson s Disease

Dementia Training Session for Carers. By Dr Rahul Tomar Consultant Psychiatrist

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

UNIVERSITY OF BOLTON SCHOOL OF EDUCATION AND PSYCHOLOGY PSYCHOLOGY PATHWAYS SEMESTER 2 EXAMINATIONS 2015/2016

PPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD

ASHI 712. The Neuroscience of Human Memory. Dr. Olave E. Krigolson LECTURE 2: Short Term Memory and Sleep and Memory

UDS version 3 Summary of major changes to UDS form packets

Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease

III./3.1. Movement disorders with akinetic rigid symptoms

EARLY ONSET FRONTOTERMPORAL DEMENTIA AND ALZHEIMERS DISEASE: DIAGNOSIS, TREATMENT AND CARE

A Neuropsychiatric, Neuroradiological, and Neuropsychological Profile of a Cohort of Patients with Vascular Dementia

Why Cognition Matters: Impact of Cognitive Impairment on Safety and Independent Living Skills

Prof Tim Anderson. Neurologist University of Otago Christchurch

The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.

MANAGING YOUR COGNITIVE SYMPTOMS. Dr. Valerie Suski University of Pittsburgh Medical Center HDSA COE Director

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

Assessment Toolkits for Lewy Body Dementia

Parkinson e decadimento cognitivo. Stelvio Sestini

Dementia. Assessing Brain Damage. Mental Status Examination

Capacity and Older Adults. Kenneth I. Shulman

Method. NeuRA Schizophrenia and bipolar disorder April 2016

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease

Imaging of Alzheimer s Disease: State of the Art

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Cronicon EC NEUROLOGY. Mini Review. Alzheimer s Living with the Disease- Understanding the Brain. Caron Leid* Aspen University, Aspen, Colorado, USA

Neuropsychology and Parkinson s Disease. Erin Holker, Ph.D., ABPP Neuropsychology Laboratory

Parkinson s Disease Psychosis: Hallucinations Delusions and Paranoia

Update on functional brain imaging in Movement Disorders

Table 7.2B: Summary of Select Screening Tools for Assessment of Vascular Cognitive Impairment in Stroke Patients

Cognitive Neuroscience of Memory

Palliative Approach to the Person with Advanced Dementia

HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.

Working Memory: Critical Constructs and Some Current Issues. Outline. Starting Points. Starting Points

Functional Neuroanatomy. IBRO ISN African Neuroscience School 4-13 th Dec 2014 Nairobi, Kenya

Transcription:

Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1

Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated with Anxiety Depression Cognitive impairment Frontal executive Excess disability Worse quality of life Poorer outcomes Caregiver distress 23 impairment Main contributors to quality of life 4 Dementia Predictors of deterioration in health-related quality of life in Parkinson's disease: results Psychosis from the DATATOP t i l 5 Are particularly common 1 Neuropsychiatry Psychiatry Mood Affect Thought Behaviour Attention Alertness Perception Memory Language/speech Intelligence Cognition Motivation/apathy Neurology Motor Sensory (tactile, pain, temperature, two-point discrimination) 1 Aarsland et al. Arch Neurol 1999;56:595 601; 2 Goetz & Stebbins. Neurology 1993;43:2227 9; 3 Marsh et al. Neurology 2004;63:293 300; 4 Schrag et al. J Meurol Neurosurg Psychiatr 2000;69:308 12; ; 5 Marras et al. Mov Disord 2008;23:653 9. 2

Wide range of behavioural and personality changes in patients with PD according to the Neuropsychiatric Inventory (NPI) n=1,351 PD patients without dementia At least one psychiatric symptom reported in 68% of the sample Psychiatric symptoms, executive impairment i and excessive daytime somnolence (EDS) were significantly more common in patients with PD >7 years duration and Hoehn & Yahr stage IV-V disease Executive impairment (phonemic verbal fluency (PF)< 10, semantic verbal fluency (SF) < 15 and alternating verbal fluency (AF) < 8 words per minute) seen in 41% of patients EDS seen in 26% of patients t Anxiety seen in 21% (Hospital Anxiety and Depression Scale) Kulisevsky et al. Mov Disord 2008;23:1889 96. To view abstract, click Abstracts link above 3

Incidence of neuropsychiatric symptoms in PD Patients with (PDD) 1 and without 2 dementia 80 PD with dementia PD without dementia (%) Patients 60 40 20 0 NPI item 1 Aarsland et al. J Neurol Neurosurg Psychiatry 2007;78:36 42; 2 Kulisevsky et al. Mov Disord 2008;23:1889 96. To view abstract, click Abstracts link above 4

Spectrum of PD cognitive impairment Predominantly subcortical items 1. Sustained attention 2. Working memory 3. Verbal memory Free and delayed recall 4. Verbal fluencies AF and action verbal fluency Predominantly cortical items: 1. Confrontation naming 2. Clock drawing (copy) 5

Cognitive impairment in PD Although precise identification of the impaired processes and their explanations in terms of cognitive models are debatable Impaired cognitive tasks in PD are very reminiscent of tasks impaired in processes affecting the frontal lobes 6

Types of cognitive impairment vary between newly diagnosed PD patients As a whole, lower cognitive performance in all tests vs control group Cortical and subcortical changes may occur simultaneously in some patients Patie ents (%) sh howing impa airment Memory and language g are more cortical than attention and visuospatial functions Muslimovic D. Neurology 2005;65:1239 45. To view abstract, click Abstracts link above 7

The most important clinical predictors of global cognitive decline in PD (corrected for age) Neurological tasks with (a more posterior) cortical basis Semantic fluency Ability to copy Intersecting pentagons figure As well as a non-tremor dominant motor phenotype at the baseline assessment Profile of cognitive dysfunction amongst PD patients at baseline and at 3.5 (+/ 0.7) years from diagnosisi Pentagons: pentagon copying; PF: phonemic fluency; PRM: pattern recognition memory; SF: semantic fluency; SRM: spatial recognition memory; TOL: Tower of London Williams-Gray et al. Brain 2007;130:1787 98. To view notes, click notes tab 8

Comparative progression of impairment of subcortical-type type (A,B) and cortical-type type (C,D) items Estimated Mar rginal Means Estimated Marg ginal Means 12 10 8 6 4 9 8 7 6 selective decrease in cortical-type items scores in PDD TOTAL SCORES independently discriminated controls from PD without dementia as well as PD without t dementia from PDD (P<0.001) A. Alternating verbal fluency B. Working memory CG Cognitively intact MCI Dementia CORTICAL SCORES independently discriminated PDD from PD without dementia (P<0.01) Estimated Marg ginal Means 6 5 4 3 2 CG Cognitively intact MCI Dementia C. Clock drawing task Copy part D. Confrontation naming CG Cognitively intact MCI Dementia PDD is characterised by the addition i of cortical dysfunction upon a predominant and progressive fronto- subcortical impairment rginal Means Estimated Mar 19 18 17 16 15 CG Cognitively intact MCI Dementia Click for further details. Pagonabarraga et al. Mov Disord 2008;23:998 1005. To view abstract, click Abstracts link above 9

Cognitive impairment in PD Cognitive impairment Normal Cognitive dysfunction Dementia Diagnosis of PD MCI * Time Age Phenotype Cortical deficits * Mild cognitive impairment Naming Pagonabarraga et al. Mov Disord 2008;23:998 1005. 10

PD cognition: the boundaries between these 'systems' are not well defined Acetylcholine impairments in memory, attention, and frontal dysfunction Noradrenaline Contributing to impaired attention Glutamate? Serotonin Depressive mood Dopamine Partly responsible for dysexecutive syndrome 11

Heterogeneity of cognitive impairment in newly diagnosed PD PD patients had lower cognitive performance in all tests vs healthy controls Overall, the PD population suffered only mild cognitive impairment Dopamine agonist (DA) Cholinergic denervation? Muslimovic D. Neurology 2005;65:1239 45. 12

Clinical features may reflect the extent of pathological burden Relatively subtle cognitive impairment i in PD (R-SCI) From visuo-perceptual and attentional-executive dysfunction PD with concurrent dementia PDD To visuo-perceptual and attentional-executive dementia Mainly dopaminergic deficits Crucial contribution of non-da systems How many legs? Hilker et al. Neurology 2005;65:1716 22. To view abstract, click Abstracts link above. To view notes, click notes tab 13

DA medication appears to have little if any influence on the epidemiology of non-motor phenomena PD patients without dementia (n=1351) Current therapeutic combinations for PD Lev+DAs Lev+DAs 16% 3% Lev+DAs+ICOMT Lev+DAs+Anticholinergics 27% Lev+DAs+Other 44% 17% 64% 3% 0% 8% 16% 2% Monotherapy DAs* Lev alone Pramipexole Lev+ICOMT 4% Cabergoline Lev+(selegiline/amantadine/other AP) 22% Ropinirole DAs+ICOMTs Pergolide Monotherapy others 51% Monotherapy DAs 23% Lev+DAs No clear relationship between pharmacological data and: NPI items (including hallucinations) Executive dysfunction EDS (Epworth questionnaire) Levodopa (Lev) used by 74.2% of the patients, either alone (27%) or mainly in combination with dopamine agonists (DAs) Kulisevsky et al. Mov Disord 2008;23:1889 96. To view abstract, click Abstracts link above 14

Evolving pharmacological response to Lev: three types of PD patients without dementia in whom DA cognitive response should be examined (1) Executive task perfor rmance Proper prefrontal cortex function De Stable responders Wearingoff PD novo PD Optimum patients (for PD) Too little DA receptor stimulation Too much Kulisevsky J. Drugs Aging 2000;16:365 79. To view abstract, click pause then click Abstracts link above 15

Evolving pharmacological response to Lev: three types of PD patients without dementia in whom DA cognitive response should be examined (2) De-novo 1 Incomplete (below normal range) cognitive improvement Working memory various frontal tasks Declines at 18 months, lost significance at 24 months Advanced PD patients (acute challenge of Lev) Stable responders to oral Lev 2 Little, if any, modification in tasks covering a wide range of cognitive domains Wearing-off 3 Acute (reversible) worsening performance in highly demanding frontal tasks Wisconsin Card Sorting Test (WCST), Sternberg paradigm, or associative conditional learning 1 Kulisevsky et al. Mov Disord 2000;15:613 26. 2 Kulisevsky J. Drugs Aging 2000;16:365 79. 3 Kulisevsky et al. Brain 1996;119:2121 32. To view abstract, click Abstracts link above. To view notes, click notes tab 16

Cognitive effects of pharmacological manipulation of the DA system Chronic DA replacement Acute DA challenge may have contrasting Improves motor and cognitive effects 1. Same task different motor response functions but is not enough to (e.g. WCST) compensate for Fuctuating patients worsening performance in On vs Off All motor deficits Returns to previous level of All cognitive deficits performance when plasma levels of LD decays Proper prefrontal cortex function 2. Same patients different tasks Executive ta ask performan nce De novo PD Too little Stable responders Wearing -off PD Optimum patients (for PD) DA receptor stimulation Kulisevsky J. Drugs Aging 2000;16:365 79. Too much Depending on frontal cortical regions with different DA depletion in PD 3. Same task - different polymorphisms Genes regulating g dopaminergic transmission COMT 4. Same patients rapid vs slower plasma increase in LD level Standard transient negative effects vs retard protecting effects 17

Cortical cholinergic activity is reduced in PD and PDD Mean Cortex Amygdata Hippocampus Inferior Temporal Superior Temporal Parietal Patients With Alzheimer Disease Patients With Parkinson Disease Without Dementia Patients With Parkinsonian Dementia Cerebral AChE activity correlates with neurological deficits in PDD Verbal memory Stroop colour word tests Trail-making test Digit it span Benton s Judgement of Line Orientation Frontal 0-5 -10-15 -20-25 -30 % Reduction in AChE Activity Hilker et al. Neurology 2005;65:1716 22; Bohnen. J Neurol 2005;253:242 7. To view abstract, click Abstracts link above. To view notes, click notes tab 18

Rivastigmine versus placebo: changes from baseline on the Alzheimer s Disease Assessment Scale cognition (ADAS-cog) Change from baselin ne, ADAS-co og 2.5 2.0 1.5 1.0 0.5 0 0.5 Rivastigmine (n=329) Placebo (n=161) * ** Improvement Baseline 1.0 Deterioration Week: 0 16 24 *P = 0.002; **P < 0.001, efficacy analysis Emre et al. N Engl J Med 2004;351:2509 18. To view abstract, click Abstracts link above. To view notes, click notes tab 19

Question 1. In Kulisevsky's 2008 study, what proportion of patients without dementia had at least one psychiatric symptom? A) 38% B) 58% C) 68% D) 97% Correct - Click anywhere to continue Incorrect, please try again Incorrect, You must please answer try again the question before continuing Submit Clear 20

Question 2: Impaired cognitive tasks in PD are very reminiscent of tasks impaired in processes affecting: A) Temporal lobes B) Occipital lobes C) Frontal lobes Correct - Click anywhere to continue Incorrect, please try again Incorrect, You must please answer try again the question before continuing Submit Clear 21

Copyright statements Slide 8 Slide 9 Slide 13 Slide 19 2007, reproduced with permission from Oxford University Press 2008, reproduced with permission from John Wiley & Sons, Inc 2005, reproduced with permission from Wolters Kluwer, Inc 2004, reproduced with permission from Massachusetts Medical Society. All rights reserved 22